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ABSTRACT
The Impact of Myoblast Transplantation on Collateral Capillary Arteriogenesis and Macrophage
Phenotype
Christine Hue Do
Gangrene, pain, loss of limb function, amputation, and death are only few of the grievous
consequences associated with peripheral arterial disease (PAD), a vascular disease caused by an
obstruction that narrows the blood vessels. Since some patients have collateral vessels that can
re-route blood to its downstream destination, much focus has been spotlighted upon discovering
the mechanism of this process, termed arteriogenesis, as well as cell therapies to increase arterial
diameter of collateral vessels. Since some patients do not have native pre-existing collateral
vessels, another method to re-route blood is through arterialized collateral capillaries (ACC),
which is the conversion of capillaries to arterioles. Because the delivery of pro-arteriogenic cell
therapies did not have much clinical success, another candidate is needed to treat PAD:
myogenic precursor cells. Preliminary, unpublished results demonstrated myogenic cell
transplantation enhanced collateral capillary arterialization. Specifically, the diameter of
arterialized collateral capillaries due to myoblast treatment is larger when compared to the
vehicle alone and untreated groups. The current working hypothesis suggests that myoblasts and
macrophages have a reciprocal paracrine interaction in which macrophages secrete cytokines and
chemokines for the myoblasts to mature, and that certain genes in myoblasts are expressed as
cytokines and chemokines to encourage macrophage recruitment and M2 macrophage
polarization, which promotes arteriogenesis. To test this hypothesis, the expression of target
genes in myoblasts would be measured using RNA sequencing and Western blotting for
measuring proteins, macrophage phenotype and quantity would be determined in vivo along with
vessel diameter with immunofluorescence staining. This senior thesis describes the studies that
would need to be completed to test the hypothesis stated above, including example images from
the immunofluorescence staining, detailed protocols, and candidate genes.

Keywords: arteriogenesis, arterialized collateral capillary, cell transplantation, satellite cell,
myoblast, macrophage phenotype, M1, M2
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INTRODUCTION
Preview: Due to the devastating impacts of peripheral artery disease (PAD) and the lack
of clinical success of current arteriogenic therapies, differentiated muscle satellite cells are a new
possible cell therapy. Unpublished results indicates that transplanting congenic primary
myoblasts increases collateral capillary arteriogenesis. The working hypothesis to explain this
observation is that myoblasts enhance arteriogenesis through paracrine interactions of signaling
proteins and/or regulatory miR molecules. To test this hypothesis, the expression of target genes
in myoblasts would be measured using RNA sequencing and Western blotting; the mouse model
of PAD is induced by ligating the lateral feed artery of the spinotrapezius muscle; and the
macrophage phenotypes, vessel diameters, and vessel count in vivo would be quantified with
antibody staining.

Figure 1. Peripheral artery disease (PAD). PAD is an ischemic condition in which plaque
accumulation from atherosclerosis narrows blood flow. Adapted from [1].
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Peripheral arterial disease (PAD) is the narrowing of arteries in the peripheral circulation
due to an arterial atherosclerosis, leading to impaired perfusion to a patient’s lower extremities
[2]. The plaque deposits from atherosclerosis accumulate in the peripheral circulation, which
reduces the blood flow usually in the lower limbs (Figure 1) [3]. More than 200 million people
worldwide have PAD, and its prevalence increases with age, reaching 20% amongst those over
55, and certain factors (e.g., obesity, diabetes, high blood pressure, smoking) can increase the
risk for PAD [4–6]. Health consequences associated with PAD are critical limb ischemia,
gangrene, amputation, intermittent claudication, ulcers, myocardial infarctions, etc. [7]. Among
these symptoms, intermittent claudication, which is leg pain while walking, is one of the most
common. Treatment methods for PAD include revascularization and exercise training programs.
Revascularization entails stenting, bypass grafting, or angioplasty surgical interventions.
However, 20-30% of patients with critical limb ischemia are ineligible for revascularization due
to comorbidities, and 25% perish within five years [8]. Those ineligible for revascularization
methods may opt for limb amputation, but 20% pass away within six months [8]. Exercise is
considered the ideal treatment method since it can naturally improve limb function without
surgical intervention. However, intermittent claudication has discouraged many patients from
complying with exercise therapy. Plus, exercise does not improve blood flow [9], so it should
accompany surgical intervention to improve patient limb function and blood flow. In fact, a
combined program of revascularization surgical intervention and exercise has been linked to
increased walking distance and improved health-related quality-of-life scores [10]. In lieu of
revascularization, promoting collateral arteriogenesis to improve patient limb function and blood
flow may be a more viable option. Coupled with exercise programs, myoblast transplantation
could be a useful therapy for those with intermittent claudication.
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Figure 2. Collaterals. Collateral vessels re-route blood around an occlusion or arterial
obstruction to restore and normalize blood flow. Adapted from [11].
Collateral vessels, which help restore blood flow by bypassing major arterial obstructions
and remodeling through arteriogenesis, enlarge to accommodate this redistribution of blood flow
to the ischemic region (Figure 2) [10, 11]. After the occlusion of an artery, blood flow is
redirected into collaterals, which increases shear stress in vessel walls and triggers collateral
remodeling (Figure 3) [12, 13]. The elevated fluid shear stress activates arteriolar endothelial
cells and increases the expression of adhesion molecules and chemokines such as MCP-1 to
stimulate the proliferation of vascular smooth muscle cells (SMCs) and endothelial cells (ECs)
and monocyte migration [12, 14, 15]. Mitogens secreted by macrophages promote cell
proliferation and monocyte migration to further recruit more macrophages and continue this
cycle of reciprocal paracrine interaction [16, 17].
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Figure 3. Collateral Arteriogenesis. Collateral artery growth in response to arterial
obstruction based on increased shear stress. Before an occlusion, blood flows through the
conductance artery (left). During an occlusion, the conductance artery experiences decreased
perfusion, which increases shear stress in the collaterals due to the blood flow redistribution
(middle). In response to the occlusion, peri-collateral macrophages migrate to promote
collateral remodeling into mature collateral arteries, which restores perfusion (right). Adapted
from [14].
Some people have pre-existing collaterals, which lead to a lower risk of a cardiac event and
increase in myocardial viability [16-18]. However, only about 30% have these pre-existing
collaterals [19, 20]. For those without, there is also collateral capillary arteriogenesis, which
arterializes arteriole-to-arteriole capillary collaterals that are a part of a highly-connected
arteriolar network, which operates in a similar manner in terms of mechanisms and control
pathways as those of arteriogenesis in pre-existing collateral vessels [24]. These arterialized
collateral capillaries (ACC) are similar in appearance to capillaries yet have enlarged diameters
and are covered with smooth muscle cells, and thus are arterioles.
Since arteriogenesis is a process mediated by growth factors, cytokines, and other
signaling molecules, delivering these known factors to the ischemic area via intramuscular or
intravenous injection is a therapeutic idea explored in both gene and protein therapy. Some proarteriogenic factors that were delivered are vascular endothelial growth factor (VEGF), fibroblast
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growth factor (FGF), hepatocyte growth factor (HGF), and monocyte chemoattractant protein-1
(MCP-1). When VEGF is delivered via gene therapy or recombinant protein into animal models,
limb ischemia was mitigated [22-24], tissue perfusion and blood flow recovery increased [25,
26], and combined with FGF, elicited a synergistic effect upon collateral artery development and
remodeling [23, 25, 27, 28]. Delivery of FGF yielded collateral artery growth [29, 30], increased
vascular permeability and muscle perfusion [34], improved blood flow and functional collateral
vessels [26, 32, 33], and increased arteriole density [37]. Therapeutic arteriogenesis by delivering
HGF have been associated with increased limb tissue perfusion, pain relief, and ankle-brachial
index [35, 36], yet these same studies performed in larger clinical trials yielded no significant
findings to indicate lessened adverse events, wound healing, or amputations [35-38]. The
chemokine process of MCP-1 encourages monocyte recruitment which secrete growth factors
that aid in outward collateral remodeling [42], though the exact mechanism in which MCP-1
promotes monocyte recruitment is unclear. Early animal studies involving intra-arterial catheter
injections of MCP-1 via an osmotic minipump demonstrated increased collateral flow and
proliferation of SMCs [43], increased collateral conductance [41, 42], improved peripheral
conductance and ratio of peripheral over aortic blood pressure [46], well-developed collateral
circulation [47], and blood flow recovery [45]. However, several studies have shown that
intramyocardial injection of MCP-1 into the infarct border zone did not result in arteriogenesis
[48], meaning MCP-1 did not improve myocardial infarctions via arteriogenesis. Plus, there are
concerns of increasing pro-atherosclerotic macrophages in the plaque with MCP-1 delivery [46,
47]. Despite promising animal studies of gene and protein therapy to induce arteriogenesis, these
potential treatments had no significant reductions in intermittent claudication, amputations, or
adverse events such as death.
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Because of the lack of clinical success in delivering pro-arteriogenic factors to treat PAD,
a different therapy was established: cell transplantation. Instead of delivering multiple factors,
local delivery of cells that secrete many cytokines, chemokines, and growth factors in
appropriate doses into sites of injury or remodeling may be more efficient. The first candidate for
cell transplantation was bone marrow derived mononuclear cells (BM-MNCs) due to the
presence of stem cells with self-renewal and differentiation properties in this population of
monocytes, lymphocytes, hematopoietic stem cells, and mesenchymal stem cells. In some animal
ischemic models, congenic delivery of BM-MNCs improved collateral circulation and limb
perfusion [51], differentiation of SMCs and ECs [52], blood flow recovery and collateral vessel
formation [53], and reduced auto-amputation and improved limb salvage [54]. However, an
unblinded and uncontrolled pilot study in humans resulted in no differences in long-term adverse
events in half of the participants and even worsened leg pain [55]. Another pilot study resulted in
two patients being re-admitted into the hospital for chest pain following the autologous bone
marrow injection [56]. A randomized, controlled trial showed no improvement in ankle-brachial
index, and transcutaneous oxygen pressure value [57]. The second iteration of cell therapy for
peripheral ischemia was bone-marrow derived mesenchymal stem cells (BM-MSCs). In some
animal ischemic models, BM-MSCs increased collateral diameters and vessel tortuosity [58],
blood flow recovery and SMCs development [54, 55], increased collateral flow [61], and
capillary arterialization [62]. Despite these positive outcomes, clinical trials performed upon
humans have mixed results. BM-MSCs do not transdifferentiate into SMCs in animal models
[62]. There was no effect of BM-MSCs improvement in terms of left-ventricular ejection at 18
months [63]. There was no difference in ankle-brachial index when comparing the BM-MSCs
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group to the control [64]. These promising therapies have encouraging pre-clinical results, but
therapeutic clinical efficacy is limited.
Since bone marrow stem cells did not result in desirable clinical outcomes, cell types
outside of the bone marrow should be considered. Another cell treatment for PAD was
endothelial progenitor cells (EPCs). In men, the levels of circulating EPCs were a good predictor
of vascular function and reactivity [65]. After transplanting human EPCs into mice with
hindlimb ischemia, blood flow recovery, capillary density, and limb salvage ratio increased [66].
In a randomized, controlled pilot study, however, there was no difference in ankle-brachial index,
wound healing, leg pain, and walking distance between the cell-treated group and the control
[67]. Yet another potential alternative is myoblast transplantation. Arising from satellite cells
during myogenesis, myoblasts are myogenic progenitor cells that are in the early stages of
developing into a muscle cell and are primarily involved in skeletal muscle repair. Since satellite
cells are activated by mechanical load, growth stimulus, and resistance exercise [68], pairing this
cell therapy with exercise may improve leg pain and walking distance. Compared to bone
marrow derived stem cells, satellite cells are native to the skeletal muscles, which allows for
intrinsic factors and external cues within the muscle stem cell niche to control their behavior [6870]. Since bone marrow derived stem cells are not a part of this niche, they may be
communicating less effectively to the surrounding cells and structures, which may contribute to
decreased effectiveness as a cell therapy. After being activated from the quiescence state, these
tissue resident stem cells recruit monocytes and macrophages. In order to enhance both vessel
and muscle growth, the monocytes and macrophages secrete cytokines and chemokines to
encourage the maturation of satellite cells into myotubes (Figure 4) [67, 68]. Myoblasts, in
particular, have pro-angiogenic responses to induced ischemia through upregulation of VEGF
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and angiopoietin, and the enhancement of neovascularization [71-73]; however, the effect of
myoblasts upon arteriogenesis is still unclear. Recent studies have shown that satellite cells
produce paracrine effects upon collateral vessel formation through EC and SMC proliferation,
and blood flow recovery [74-77], thus displaying that myoblasts may also have pro-arteriogenic
effects.

Figure 4. Myogenesis. Process of tissue injury activating satellite cells into myoblasts.
Monocyte and macrophage recruitment help muscle growth and maturation into myotubes.
Adapted from [81].
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Though EC and SMC proliferation are common characteristics of arteriogenesis,
macrophages are the primary regulators of arteriogenesis [79-81]. There are two ends of the
macrophage phenotype spectrum: classically activated (M1) and alternatively activated (M2)
[85]. M1 macrophages are pro-inflammatory with pathogen-killing capabilities, while M2 are
anti-inflammatory and focus on tissue repair and cell proliferation [80, 81]. By releasing proarteriogenic and anti-inflammatory cytokines, chemokines, and growth factors, M2 macrophages
enhance arteriogenesis (Figure 5) [83-85].

Figure 5. M2 macrophages giving rise to vessel maturation. Ischemic region induces several
cytokines to be released, one of which polarizes M2 macrophages to release pro-angiogenic and
pro-arteriogenic factors. Adapted from [89].
Since monocytes and activated satellite cells have reciprocal paracrine interactions [90], it is
hypothesized that myoblasts secrete certain factors that promote arteriogenesis by inducing M2
macrophage polarization. If the myoblasts do secrete pro-arteriogenic factors, then there must be
certain genes that translate for these factors. Recent evidence has suggested that specific
microRNAs (miRNAs), conserved non-coding regions of RNA molecules that regulate
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complementary mRNA sequences by binding to the 3’-untranslated regions of targeted mRNA to
result in post-transcriptional gene silencing in which the mRNA is degraded or blocked from
translation [91], are involved in a pathological process of PAD [92-96]. In fact, there are several
myoblast genes that are correlated to various pro-arteriogenic responses, such as EC proliferation,
EC migration, SMC proliferation, EC migration, monocyte recruitment, and macrophage
polarization. EC proliferation is linked to miR-352 [97], miR-93 [98], miR-100 [99], miR-27a/b
[100], miR-23 [101], miR-15b-5p [102], miR-155 [103], miR-let-7g [104, 105], miR-106b [106],
miR-126 [107, 108], miR-495 [109], miR-329[109], miR-15a [110], miR-503 [111], miR-223
[112], and miR-17~92 [113, 114]. EC migration is linked to miR-146a [115], miR-27a/b [100],
miR-23 [101], miR-150 [116], miR-15b-5p [102], miR-106b [106], miR-126-3p [117], miR-126
[107, 108], miR-495 [109], miR-15a [110], miR-352 [97], miR-503 [111], miR-223 [112], miR17~92 [113, 114], and miR-92a [118]. SMC proliferation is linked to miR-143-3p [119], miR-93
[98, 120], and miR-199a-5p [121]. SMC migration has been linked to miR-100 [99]. Monocyte
recruitment is linked to miR-199a-5p [122], miR-27b [123-126], and miR-146a [115].
Macrophage polarization has been linked to miR-93 through down-regulation of proinflammatory cytokines [98, 127]. A table of these genes and their correlated pro-arteriogenic
result is summarized in Table 1. Some miRNA target databases have found that one miRNA can
regulate several gene targets, whereas a single gene could also be the target for several miRNAs
though some studies have determined a one-to-one relationship between the miRNA and its
target gene [91]. Other studies have suggested that a cluster of miRNAs can work in conjunction
to regulate a gene [91, 128-129]. Based on the summary of myoblast miRNAs in Table 1, there
are some miRNAs that have multiple pro-arteriogenic targets, as shown in Table 2. Most notable
from this table is that miR-27b and miR-93 have the most pro-arteriogenic targets. miR-27b
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results in the upregulations of EC proliferation, EC migration, and monocyte recruitment, while
miR-93 is linked to upregulations of EC proliferation, SMC proliferation, and macrophage
polarization.
Table 1. Summary table of myoblast miRNAs and pro-arteriogenic targets
EC
EC
SMC
SMC
Monocyte
Macrophage
Proliferation Migration
Proliferation Migration
recruitment
polarization
miR-352
miR-146a
miR-143-3p
miR-100
miR-199a-5p miR-93
miR-93
miR-27a/b
miR-93
miR-27b
miR-100
miR-23
miR-199a-5p
miR-146a
miR-27a/b
miR-150
miR-23
miR-15b-5p
miR-15b-5p
miR-106b
miR-155
miR-126-3p
miR-let-7g
miR-126
miR-106b
miR-495
miR-126
miR-15a
miR-495
miR-352
miR-329
miR-503
miR-15a
miR-223
miR-503
miR-17~92
miR-223
miR-92a
miR-17~92

EC
Proliferation
miR-352
miR-93
miR-100
miR-27a/b
miR-23
miR-15b-5p
miR-106b
miR-126
miR-495
miR-15a
miR-503
miR-223
miR-17~92
--------------

Table 2. Myoblast miRNAs with multiple pro-arteriogenic targets
EC
SMC
SMC
Monocyte
Macrophage
Migration
Proliferation Migration
recruitment
polarization
miR-352
-----------------------------------miR-93
--------------miR-93
--------------miR-100
--------------miR-27a/b
-------------miR-27b
-------miR-23
--------------------------miR-15b-5p
--------------------------miR-106b
--------------------------miR-126
--------------------------miR-495
--------------------------miR-15a
--------------------------miR-503
--------------------------miR-223
--------------------------miR-17~92
--------------------------miR-146a
------------miR-146a
------------miR-199a-5p ------miR-199a-5p -------
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The working hypothesis for this thesis is that there are some miRNAs in myoblasts that
affect arteriogenesis. To test the effects of myoblast-enhanced arteriogenesis, the following
methods would be used: RNA sequencing of miRNAs in myoblasts; measuring the expression of
proteins and miRNA candidates; inducing a PAD murine model through ligation surgery;
myoblast transplantation following the ligation surgery; and after cell transplantation, measuring
the vessel diameter, quantifying the vessel amount, and phenotyping the macrophages in vivo.
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METHODS
Animal Husbandry
All pilot procedures were performed according to protocols approved by Cal Poly’s
Institutional Animal Care and Use Committee (IACUC). Male BALB/C (n=12) mice (Taconic
Farms, Oxnard, CA) and ICR mice were used for all experiments. All mice were housed at the
University Vivarium in microisolator cages with access to water, food, and enrichment (bedding
and ‘mouse house’). This facility operates on a 12-hr light:12-hr dark cycle with temperaturecontrolled rooms. All animals were inspected daily. The ICR mice were used during antibody
staining training. The BALB/c mice were divided into the following groups: ligation surgery
only control (n=4), vehicle (n=4), and myoblast-vehicle transplantation (n=4).

Surgery
The purpose of the surgery is to model ischemia and the growth of collateral arteries and
macrophage migration by ligating the spinotrapezius lateral feed artery. Mice were anesthetized
in the induction chamber with 5% isoflurane mixed into oxygen and flowing at 3 L·min-1 oxygen
flow. After checking the mouse’s righting reflex, the mouse was weighed and placed on the
preparatory stage with 2-3% isoflurane mixed into oxygen and flowing at 0.5-1.5 L·min-1.
Ophthalmic ointment was applied to the corneas to prevent desiccation. Trimming clippers and
depilatory cream were used to remove hair bilaterally on the dorsal surface. The area was
disinfected with chlorhexidine diacetate. The mouse received a subcutaneous buprenorphine
(0.075 mg/kg) injection as an analgesic. After transferring the mouse to the surgical platform, the
mouse’s core temperature was monitored by rectal thermistor probe and maintained at 35˚C and
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kept constant with a heating pad. An initial incision was made on the lateral edge of the
spinotrapezius muscle parallel to the spine (Figure 6).

Figure 6. Location of Ligation and Myoblast-Vehicle Treatment Delivery. The location of
the spinotrapezius ligation is lateral to the muscle, while the treatment delivery location is above
the ligation site. Adapted from [130].
After blunt dissecting the fascia and undermining the superficial fat pad to find the deep fat pad
under the spinotrapezius muscle, the artery-vein pair was found. After separating the artery from
the pair, the artery was ligated in two locations using silk sutures and transected between the
ligatures. The incision was closed using a 7-0 prolene suture. This same surgical procedure was
repeated on the sham side, though the artery was not ligated nor transected. The mouse was
given another dose of a buprenorphine injection following the procedure. Injections were also
given 24- and 48-hours post-ligation and more if necessary. A more detailed protocol of the
ligation surgery is in Appendix A1. Example images of arterialized collateral capillaries and
capillaries following the ligation surgery are in Figure 7.
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A

B

C

D

Figure 7. Example images arterialized collateral capillaries (ACC) following ligation
surgery. Adapted from [130]. A) Female mouse ligated with ACC in red. B) Female mouse
ligated with capillaries in blue. C) Male mouse ligated with ACC in red. D) Male mouse ligated
with capillaries in blue.

Cell Culture
The purpose of culturing satellite cells into myoblasts is to have cells ready for
transplantation. Satellite cells would be isolated from young male C57BL/6 mice were from the
extensor digitorum longus (EDL) muscle. The excised EDL muscle were digested with Type II
15

Collagenase and placed in a tissue culture media dish for myofiber separation. To isolate
myofibers, the muscles were gently mechanically agitated by tituration. Live fibers were placed
in cell culture flask. More detailed protocols about satellite cells and myoblasts are in
Appendices A2 for satellite cell isolation and A3 for myoblast expansion. Myoblast cultures
were assessed through the phase-contrast microscope daily, feed every two days, and passaged
every 3-5 days. Directly after satellite cell isolation, however, feeding and passage does not
occur until day 5 and 7, respectively. Once cells appeared to have a myoblast morphology, they
were either frozen or seeded onto the gelatin vehicle for transplantation. More detailed protocols
about cell culture are in Appendices A4 for solution preparation, A5 for cell passage and feeding,
and A6 for cell freeze and thaw.

Gelatin Preparation and Myoblast Transplantation
The purpose of preparing a gelatin hydrogel is to form a vehicle that keeps cells viable
during the transplantation process. A 10% gelatin vehicle would be prepared and polymerized in
a 24-well plate to encourage cell viability and attachment. After polymerization, the gelatin was
cross-linked with 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide at 4˚C overnight. After
myoblasts were seeded onto the gelatin, the vehicle was incubated in growth media at 37˚C prior
to transplantation. A more detailed protocol is in Appendix A7.
After the ligation surgery, blunt dissection was performed under the spinotrapezius
muscle to create a space for insertion (Figure 6). A gelatin disc was cut with a biopsy punch (1.5
mm, 33-31A-P/25, Integra York PA Inc.) and gently inserted cell-side up.
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Perfusion Fixation
After 7 days post-surgery, all mice were euthanized by exsanguination and fixed with
paraformaldehyde in preparation for muscle immunofluorescence staining. Prior to the
euthanasia, the surgical wound was opened, and connective tissue around the spinotrapezius
muscle was gently removed. After performing a thoracotomy, a 20G needle connected to 40 mL
of vasodilator solution was pierced into the apex of the left ventricle (Figure 8); this cocktail was
composed of 0.1 unit·mL-1 heparin (MWI Animal Health), 1.5 x 10-6 mol·mL-1 adenosine
(A9251, Sigma-Aldrich), 2.5 x 10-5 mol·mL-1 sodium nitroprusside (71778, Sigma-Aldrich), and
38 mL PBS. This solution was infused at a rate of 5 min·mL-1 with a syringe pump to clear the
circulation and fully dilate the vasculature. After clearing the circulation, 4% paraformaldehyde
was perfused at a rate of 4 min·mL-1 to fix the tissues and muscles and prevent decay. Muscles
were resected and stored in PBS at 4˚C until stained. A detailed protocol is in Appendix A8.

Figure 8. Needle Piercing Apex of Left Ventricle during Perfusion Fixation.

Immunofluorescence Staining and Imaging
All muscles were permeabilized in 2% Triton X-100 (detergent, 97063-996, VWR) for 2
hours. Then, the spinotrapezius muscles were immunostained with antibodies to visualize
arteriole and macrophages. To label smooth muscle actin present on arterioles, 1:200 smooth
muscle anti-actin (clone 1A4 Cy3 antibody, C6198, Sigma-Aldrich) was used. To label
capillaries, 1:100 isolectin GS-1B4 (Alexa Fluor 647, I32450, Invitrogen) was used. To label all
macrophages, 1:100 anti-CD68 (Alexa Fluor 488 FA-11, 53068180, eBioscience at Fisher Sci)
17

was used as a pan-macrophage marker. To label M1 macrophages, 1:200 anti-CD11c (Alexa
Fluor 532 N428 Clone, 58011482, Fisher Sci) was used. To label M2 macrophages, 1:200 antiCD206 (Alexa Fluor 594 C068C2 clone, 141726, BioLegend) was used. All antibodies were
prepared in conjunction in PBS with 0.1% Triton X-100, and 2% BSA (A2153, Sigma-Aldrich)
to permeabilize plasma membranes and block nonspecific binding, respectively. This antibody
solution was incubated at 4˚C with each muscle for 24 hours. The muscles were washed with
0.1% Triton X-100 4 times for 10 minutes each at room temperature and in PBS once for 30
minutes. Muscles were mounted on incubation chambers, microscope slides with silicone casing,
with 50/50 PBS/glycerol solution. The slides were imaged on a confocal microscope (Olympus
FV-1000, Olympus) using the 10x and 20x lens objectives. Regions of interest that were imaged
are in Figure 9, chosen specifically to observe the ischemic and perfused arterialized collateral
capillaries (ACC) of arteriolar trees in the muscle [130]. A detailed protocol is in Appendix A9.
Example images of αSMA-stained arterioles, lectin-stained capillaries, CD68-stained
macrophages, and their composites are in Figure 10.
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Figure 9. Muscle Imaging Regions. Spinotrapezius muscles were imaged at three locations
between arteriolar trees where ACCs are. Scale bar is 1 mm. Red is arteriole staining, while the
blue is lectin. Adapted from [24, 130].
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Figure 10. Immunofluorescent stained arterioles, capillaries, and macrophages. (A-C)
Composites of arterioles, capillaries, and macrophages. (D-F) αSMA-stained arterioles in red.
(G-I) Lectin-stained capillaries in blue. (J-L) CD68-stained macrophages in green.
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Image Analysis
FIJI ImageJ Version 2.0.0 image software was used to quantify confocal images. The
images were split into three channels based on lasers. The z-slices were collapsed into max
intensity based on the number of slices. Each channel was colorized accordingly: red for αSMAstained arterioles, blue for lectin-stained capillaries, green for CD68-stained macrophages,
yellow for CD206-stained M2 macrophages, and orange for CD11c-stained M1 macrophages.
The brightness and contrast were adjusted to limit background staining. αSMA-positive vessels
and lectin-positive vessels were hand-counted in the compressed image. To determine the max
ACC diameter, the largest ACC was found, and a line was drawn perpendicularly across the
vessel and measured (Figure 11a). To quantify macrophages, the images were converted to
binary and analyzed for particles using a cell counter (Figure 11b). Example data measured from
Figure 10 is displayed in Table 3.

A

B

Figure 11. Image Analysis of Vessel Diameter and Macrophage Count. A) Vessel diameter
measurement of Figure 10D. B) Macrophage count of Figure 10J after setting image to binary.
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Table 3. Vessel diameter, vessel count, and macrophage count of Figure 10.
αSMA - Vessel Diameter (µm) Lectin – Vessel Count CD68 – Macrophages Count
29.1

25

1047

31

26

416

4.45

29

303

Statistical Methods
MINITAB 19 Version 19.2020.2.0 statistical software for Macintosh was used for
statistical analysis. Differences in # of ACC, maximum diameter, macrophage amount and
phenotype in sham and ligated muscles were determined by independent t-tests. One-way
ANOVA and post-hoc Tukey test determined differences between the ligation only, vehicle, and
myoblast-vehicle groups in # of ACC, maximum diameter, CD68-, CD11c-, and CD206-positive
cells in sham and ligated muscles. A p<0.05 indicated statistical significance. Data are presented
in mean±SE.
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CONCLUSION
Due to the abominable consequences of peripheral artery disease such as gangrene, limb
amputation, and death, a therapy is needed to treat peripheral artery disease and re-route blood
downstream. A method to bring blood downstream is through arteriogenesis, which is the
remodeling of collateral vessels to increase vessel diameter and restore blood flow. Despite the
various cell therapies that have been identified to aid arteriogenesis, they have not yielded
positive clinical outcomes. Preliminary, unpublished data suggests that using myogenic precursor
cells can promote arteriogenesis. It is hypothesized that the microRNAs from these cells are
related to smooth muscle cell proliferation, smooth muscle cell migration, endothelial cell
proliferation, endothelial cell migration, monocyte recruitment, and macrophage polarization; all
of which are markers of successful arteriogenesis. This proposal seeks to test this hypothesis
through RNA sequencing for candidate genes, measuring proteins via Western Blotting, murine
model of PAD by artery ligation surgery, cell transplantation, and immunofluorescent staining to
quantify vessel diameter changes and macrophage phenotypes.
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APPENDICES
Appendix A: Experimental Protocols
Appendix A1: Spinotrapezius Lateral Feed Artery Ligation Surgery Protocol
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Appendix A2: Myofiber Isolation Protocol
Myofiber Isolation
Purpose
To excise whole mouse Extensor Digitorum Longus (EDL) muscles, isolate individual live
myofibers from whole muscles, and plate live myofibers in culture conditions to facilitate the
primary culture of myoblasts.
Necessary Material


























Wash media (10% FBS in Base Media)
Base media (1% Pen-Strep in HAMs F10)
Growth media (20% FBS in Base Media)
SB 203580 working solution (5 mM)
bFGF working solution (1μg/mL)
Collagenase II solution (2mg/mL)
Horse Serum (HS)
ECM coating solution (1:100)
18 MΩ Water
T 12.5 flask (cell culture treated)
10 cm TC dishes (x5)
15 mL conical tubes

Sterile Filter System
Sterile PBS (1x)
P1000 micropipette aid and tips
P20 micropipette aid and tips
Standard pattern forceps
Curved iris scissors
5/45 Forceps (x2)
Beveled long bore glass pipettes
Cotton swabs
2x2, 4x4 gauze pads
Isopropyl Alcohol (IPA)
Styrofoam working surface

Mouse Information
Age: ___________(3-4 week)
Sex:____________
Weight:_________
Genotype:_______
TC Dish Preparation
1. ___ Coat a T12.5 with 0.5 mL ECM coating
2. ___ Allow final plate to coat overnight on rocking platform (~ 10 rpm)
3. ___ In the morning wash plate with sterile PBS
a. 10 minutes per wash on rocking platform (~ 10 rpm)
b. 2 washes
c. Wash with wash media (Sterile filter media)
Collagenase Incubation Solution
1. ___ Weigh out 6 mg of type II collagenase
2. ___ In BSC combine with 3 mL of Base Media
3. ___ Resuspend well
Muscle Fiber Wash Plates
1. ___ Defrost aliquot of HS
2. ___ In BSC, Coat 4x 10cm dishes in HS
a. Label TC dishes 1-4
35

b. Pipette 7 mL of HS into first 10 cm dish
c. Transfer HS between dishes
d. Place remaining HS in 15 mL conical and place in 37⁰C water bath
e. Aspirate excess HS from TC dishes
3. ___ Place 15 mL of wash media into Dish 1
4. ___ Place 5 mL of wash media into Dishes 2-4
5. ___ Warm plates in 37⁰C, 5% CO2 incubator
Muscle Excision – Extensor Digitorum Longus (EDL)
1. ___ Euthanize mouse
2. ___ Use insulin syringe needles to secure fore and hind limbs to Styrofoam working
surface
3. ___ Thoroughly spray hindlimbs with IPA
4. ___ Carefully remove the skin of both hindlimbs
a. The hindlimb should be exposed from the knee joint to the midpoint of each foot
5. ___ Carefully remove connective tissue around the Tibialis Anterior (TA) Muscle
a. Make sure to expose the origin of the EDL at the knee
6. ___ Create a pocket deep to the distal TA tendon below the ankle
7. ___ Cut the distal TA tendon
8. ___ Holding the TA by its distal tendon, pull it towards the knee cutting away connective
tissue as needed to separate it from the EDL
9. ___ Cut the TA at its origin and set aside to expose the EDL
10. ___ Create a pocket deep to the distal EDL tendon
11. ___ Cut the Distal EDL tendon
12. ___ Holding the cut tendon, carefully pull EDL towards the knee separating it from the
surrounding tissue
a. Avoid stretching the muscle as it will damage individual myofibers
13. ___ Cut the proximal EDL tendon
a. Tendon to Tendon isolation is critical to maintain fiber integrity
14. ___ Place EDL muscle into 3.0 mL of collagenase solution
15. ___ Repeat process for contralateral hindlimb
a. placing muscles in collagenase solution more than 5 min apart will lead to uneven
digestion
Muscle Digestion
1. ___Place 15 mL conical with EDL muscles and collagenase in 37⁰C water bath
2. ___ Repeatedly invert the 15 mL conical for every 10 min of incubation
3. ___ Incubate for 10 min
a. Digestion can take between 10-30 min depending upon collagenase activity
4. ___ Following 10 min, remove 15 mL conical every 5-10 min and inspect for proper
digestion
a. Use dissecting microscope light on brightest setting for lighting
b. When properly digested individual myofibers should begin to protrude from the
surface of the muscle belly
c. If the muscle appears fuzzy under a dissecting microscope or individual fibers
appear fat and milky in color, the muscle has been overdigested
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5. ___ Upon proper digestion level, remove 15 mL conicals with HS and muscles from the
water bath
6. ___ Spray conicals down with IPA
7. ___ Remove dish 1 from incubator
8. ___ Coat glass pipettes in HS
9. ___ Use glass pipettes to remove muscles from the 15 mL conical and transfer into the
first dish
a. Place both muscles into the first dish
b. Place collagenase solution back into the water bath (in case further digestion is
needed)
10. ___ Use glass pipettes to dissociate muscles
a. Progressively use smaller bevel pipettes as the muscle becomes more dissociated
b. The muscle should only be washed with media or gently pipetted up and down
11. ___ Coat P1000 pipette tips with HS
12. ___ Use a dissecting scope and P1000 pipette to pick out individual live myofibers from
the dish
a. Live myofibers will appear shiny or clear and be straight or crinkly
b. Dead myofibers will appear opaque and bent or short
13. ___ Place all live fibers in the next numbered dish
a. Muscles should not remain out of the incubator for more than 10 min
14. ___ Repeat transfer process for the other wash dishes
15. ___ Transfer fibers as described into the ECM coated dish
16. ___ In a BSC, add 2 μL bFGF solution per 1mL of media
17. ___ In a BSC, add 2 μL P38 inhibitor solution (5mM) per 1mL of media
18. ___ Place final dish back in the incubator
a. Myoblasts should begin to migrate from the myofibers within 3 days
b. Feed after 5 days (Partial media change performed by transferring old media into
a conical with 5mL of fresh warm media and transferring 5mL of the solution into
the flask)
19. ___ Passage cells upon local confluence or average 80% confluence

NOTES:
 EDL muscles will have individual fibers protruding from the surface and slightly
separate in the body of the muscle when properly digested
 The use of a wash dish (dish 4) is only necessary if a large number of dead or fragments
of fibers are impeding the aspiration of live fibers only. You only want to aspirate live
fibers
 Cells should be passed when large, dense (80% confluent) colonies appear around fibers.
If cells start to elongate (starting to differentiate), they should also be passed
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Appendix A3: Myoblast Expansion Protocol
Primary Myoblast Expansion Protocol
Date:
Purpose: To expand primary mouse myoblasts from live Extensor Digitorum (EDL) muscle fibers
Necessary Materials:
• Growth Media (20% FBS in Base Media)
• SB 203580 working solution (10 mmol)
• bFGF working solution (1μg/ml in PBS)
• Cell Dissociation Solution - EDTA (Fisher 13151014 )
• Trypsin/EDTA (0.05% Invitrogen 25300-062)
• PBS (-/-, Ca+2, Mg+2)
• ECM coated flask
1. ___ Obtain an ~80% confluent culture vessel
a. myoblasts will begin to differentiate and form myotubes as they approach confluency
2. ___ Clean Phase Contrast Microscope with 70% v/v Isopropanol (IPA)
3. ___ Image save pictures of the culture with a phase contrast microscope
4. ___ Determine passage ratio to be used
a. myoblasts should not be split at a ratio higher than 1:3
5. ___ Choose passaging method based upon goals and culture conditions
a. use Trypsin for:
i. for better cell distribution, single cell suspension
ii. for a confluent flask with low overall confluency (1:1 pass)
b. use EDTA for:
i. preservation of surface receptors (integrins)
ii. selective passaging (more differentiated cells will more strongly adhere)
Trypsin Passaging
1. ___ Warm Trypsin and Growth Media in 37C H2O bath immediately before use
2. ___ Aspirate media from culture vessel
3. ___ Wash with PBS (-/-) and aspirate
4. ___ Add warm trypsin
a. 0.04 ml/cm2 surface (T12.5 - 0.5 ml, T75 - 3 ml)
5. ___ Immediately place in incubator for ~2 min
6. ___ Observe with phase contrast microscope
a. cells should begin to ball up and become phase bright
7. ___ Hit the flask repeatedly to dislodge weakly adherent cells
8. ___ Observe under the phase contrast microscope to ensure detachment of all cells
a. If cells are still attached, return them to the incubator for an additional min and repeat
9. ___ Add the same volume of Growth Media as trypsin to stop enzymatic cleavage
10. ___ Wash the surface of the culture vessel with the cell suspension
11. ___ Label a 15 ml conical tube and transfer the cell suspension
12. ___ Centrifuge at 300g for 5 min to create a cell pellet
13. ___ Aspirate media from the conical
a. be careful to avoid aspirating the pellet
14. ___ Resuspend in the volume of growth media (+ factors) appropriate for the chosen passage ratio
15. ___ Repeatedly pipette up and down to break of cell clumps
16. ___ Rock the culture vessel repeatedly: forward/back and left/right to evenly disperse the cells
a. Even cell distribution can be checked under the phase contrast microscope
17. ___ Place in incubator
a. close the door gently to prevent uneven cell distribution
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Appendix A4: Cell Culture Solution Preparation Protocol
Solution Preparation
Purpose:
To prepare media and substrate for the isolation and culture of murine myoblasts
Necessary Materials









Hams F10 Nutrient Mixture
(SH3002501)
Fetal Bovine Serum (FBS)- Fisher
(SH3091003IR)
basic Fibroblasts Growth Factor
(bFGF)- Fisher (CB40060)
SB 203580 (P38/MAPK inhibitor) –
Fisher (120210)
Reconstituted Powdered DMEMFisher (31600034)
ECM (E1270-1ML)








Penicillin/Streptomycin (PenStrep)Omega
(PS-20 / 500)
18 MΩ H2O
Sterile PBS (1x)
1 M Hydrochloric Acid (HCL)
1 M Sodium Hydroxide (NAOH)
Sodium Bicarbonate (NAHCO3)
Sterile Filter (low protein binding)

5. ___ Aliquot remaining ECM into 1.5mL
micro centrifuge tubes
a. Avoid multiple freeze/thaw
cycles
Base Media
1. ___ In a BSC add 5 mL Penstrep to 500
mL bottle of Hams F10
2. ___ Label Base Media and store up to 3
months at 4C
Wash Media
1. ___ In BSC add FBS to Base media
(10% FBS v/v)
2. ___ Sterile filter media (optional)
3. ___ Label Wash media and store at 4C
a. only heat aliquots in 37C H2O
bath immediately before use
Growth Media
1. ___ Obtain Wash Media (only make
enough to use for up to 1 week) /
2. ___ Add bFGF working solution @ 2ul
to every 1ml of media
3. ___ Add SB 203580 working solution @
2ul to every 1ml of media
4. ___ Label Growth media and store at 4C
a. only heat aliquots in 37C H2O
bath immediately before use

bFGF working solution
1. ___ In a Biological Safety Cabinet (BSC)
dilute bFGF in 0.1% BSA in PBS to a final
concentration of 1μg/mL
2. ___ Aliquot into 1.5 ml micro centrifuge
tubes
a. 50 μl, 100μl aliquots recommended
b. Store at -20C for 3 months
c. use upon thawing if possible, avoid
additional freeze/thaw cycles
SB 203580 working solution
1. ___ In a BSC dilute in sterile DMSO to a
final concentration of 5 mM
2. ___ Aliquot into 1.5 ml micro centrifuge
tubes
a. 50 μl, 100μl aliquots recommended
b. Store at -20C for 1 month
c. use upon thawing
ECM Coating Solution
1. ___ Obtain ECM from -20C freezer
2. ___ Thaw in 4C fridge (prevent gelation)
3. ___ Keep ECM on ice at all times to
prevent gelation
4. ___ In BSC dilute ECM 1:200 in Hams
F10
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Appendix A5: Cell Culture Protocol
General Cell Culture Protocol
Materials
 Flask
 Pipet-Aid & Serologicals
 Media




Trypsin (Myoblasts: EDTA)
15ml conical

Cell Passing
1. Obtain new flask aseptically
2. Label new flask with cell type, passage number, initials, and date
3. Obtain media
4. Transfer media to new flask & place in incubator for 30 minutes
5. Transfer media to 15-ml conical (for deactivating trypsin) & place in water bath for 15
minutes
6. Obtain trypsin & place in water bath
7. Vortex trypsin thoroughly to activate enzyme
8. Aspirate media from old flask
9. Transfer PBS to old flask (5-10 ml) and rinse
10. Pipet-mix trypsin & transfer to old cells; incubate ~5min
a. 3ml to T75
b. 0.5ml to T12.5
11. Retrieve new flask
12. Inspect dissociation in old flask
13. Once dissociated, add inactivation media and titurate 6-8x
a. 12ml to T75
b. Max 5ml to T12.5
14. Aspirate entire contents & transfer to new flask
15. Gently mix cells by tilting the flask and place in incubator
Cell Feeding
1. Aliquot media into 15ml conical and place in water bath for 15 minutes
a. 12ml for T75
b. Max 5ml for T12.5
2. Aspirate old media out of flask
3. Transfer warm fresh media into the flask
4. Lightly swish media in flask
5. Place flask in incubator
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Appendix A6: Cell Freeze/Thaw Protocol
General Freeze Protocol
Materials
 Media
 PBS
 1mL Cryovials
 Sterile filter
 15mL conical
Freeze
1.
2.
3.
4.
5.
6.

7.
8.

9.
10.
11.
12.
13.






 100μL vial
Cooling liner
DMEM
DMSO
FBS

 Trypsin (Myoblasts: EDTA)
 AO/PI stain (Cell count)
 Flask
 P1000
 Pipette aid + Serologicals

Make freeze media (5ml). 70%DMEM 20%FBS 10%DMSO, sterile filtered.
Obtain trypsin & place in water bath
Vortex trypsin thoroughly to activate enzyme
Aspirate media from old flask
Transfer PBS to old flask (5-10 ml) and rinse
Pipet-mix trypsin & transfer to old cells; incubate ~5min
a. 3ml to T75
b. 0.5ml to T12.5
Inspect dissociation in old flask
Once dissociated, add inactivation media and titurate 6-8x
a. 12ml to T75
b. Max 5ml to T12.5
Aspirate entire contents & transfer to 15mL conical
Transfer 18μL into 100μL vial
Centrifuge solution at 200g (0.2 rcf) for 6 minutes
Add 2μL of AO/PI solution to 100μL vial. Transfer to counting slide and count
Aspirate media leaving pellet of cells and resuspend in corresponding amount of freeze media (1
million cells per 1mL) by triturating
Aliquot 1mL of cell solution into each cryovial
Quickly move to cooling liner and store at -80°C overnight
Transfer to liquid nitrogen storage

14.
15.
16.
Notes
 Myoblast freeze media: 90%FBS 10%DMSO

Thaw
1. Transfer media to new flask & place in incubator for 30 minutes (label flask)
2. Transfer 9ml of media to 15-ml conical (for deactivating DMSO) & place in water bath for 15
minutes
3. Remove cryovial from Dewar and thaw in water bath by swirling
4. Transfer cell solution into 9ml of warm media and triturate (work fast after thawing as DMSO is
toxic to cells)
5. Centrifuge solution at 200g (0.2 rcf) for 6 minutes
6. Aspirate media leaving pellet of cells and resuspend in 1ml of media by triturating
7. Transfer cell suspension into T75 with 12ml of prewarmed media
8. Lightly swirl flask to ensure even cell distribution and place in incubator
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Appendix A7: Sterile Gelatin Preparation Protocol
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Appendix A8: Perfusion Fixation Protocol
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Appendix A9: Spinotrapezius Muscle Staining and Imaging Protocol
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